Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

when it rose 4.92% --Up 2.14% year-to-date --Down 40.2% from its all-time closing high of $146.91 on June 25, 2024 --Down 18.70% from 52 weeks ago (Jan. 26, 2024), when it closed at $108.07 --Down ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's recent climb ... is even more heartbreaking for Bills with this angle 5 Best Pickup Trucks for Retirees on a Budget As DeepSeek ...

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

HoYoverse has announced the date and time for the upcoming Genshin Impact 5.4 livestream. Usually, the Special Program is conducted 12 days before a new version update, but this time the premiere ...